BidaskClub downgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a sell rating to a strong sell rating in a report published on Tuesday.

Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, October 27th. Raymond James Financial cut shares of Amphastar Pharmaceuticals from an outperform rating to a market perform rating and set a $18.00 price objective for the company. in a research report on Thursday, November 9th. Piper Jaffray Companies reaffirmed a buy rating and set a $19.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Sunday, September 17th. BMO Capital Markets lifted their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a market perform rating in a research report on Friday, November 10th. Finally, Needham & Company LLC lifted their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a buy rating in a research report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. Amphastar Pharmaceuticals currently has an average rating of Hold and a consensus target price of $19.50.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down $0.10 during mid-day trading on Tuesday, reaching $17.82. 169,281 shares of the company’s stock traded hands, compared to its average volume of 196,843. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. Amphastar Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $19.95. The stock has a market cap of $819.29, a PE ratio of 120.40, a PEG ratio of 1.27 and a beta of 1.69.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The company had revenue of $57.90 million during the quarter, compared to analysts’ expectations of $57.23 million. During the same quarter last year, the company posted $0.14 EPS. The firm’s revenue was down 9.8% compared to the same quarter last year. sell-side analysts predict that Amphastar Pharmaceuticals will post -0.03 earnings per share for the current fiscal year.

In related news, CFO William J. Peters sold 6,226 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $19.67, for a total transaction of $122,465.42. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Stephen B. Shohet sold 7,862 shares of the business’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $18.73, for a total transaction of $147,255.26. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 92,060 shares of company stock worth $1,716,956. 11.10% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nationwide Fund Advisors lifted its holdings in shares of Amphastar Pharmaceuticals by 11.9% in the second quarter. Nationwide Fund Advisors now owns 49,266 shares of the company’s stock valued at $880,000 after purchasing an additional 5,233 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Amphastar Pharmaceuticals by 2.0% in the second quarter. Northern Trust Corp now owns 485,706 shares of the company’s stock valued at $8,675,000 after purchasing an additional 9,672 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Amphastar Pharmaceuticals by 70.2% in the third quarter. BNP Paribas Arbitrage SA now owns 17,946 shares of the company’s stock valued at $321,000 after purchasing an additional 7,401 shares in the last quarter. Argent Capital Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the second quarter valued at about $1,069,000. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 7.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 218,080 shares of the company’s stock valued at $3,895,000 after purchasing an additional 14,646 shares in the last quarter. 44.14% of the stock is currently owned by institutional investors.

WARNING: “BidaskClub Downgrades Amphastar Pharmaceuticals (AMPH) to Strong Sell” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/bidaskclub-downgrades-amphastar-pharmaceuticals-amph-to-strong-sell/1801838.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.